CHING-WEI DAVID TZENG to Erlotinib Hydrochloride
This is a "connection" page, showing publications CHING-WEI DAVID TZENG has written about Erlotinib Hydrochloride.
Connection Strength
0.157
-
EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients. J Surg Res. 2007 Nov; 143(1):20-6.
Score: 0.069
-
Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Ann Surg Oncol. 2007 Jul; 14(7):2150-8.
Score: 0.067
-
ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. Cancer Biol Ther. 2010 Sep 15; 10(6):555-63.
Score: 0.021